Study of CT-2584 HMS in Cancer Patients
Author Information
Author(s): Cheeseman S L, Brannan M, McGown A, Khan P, Gardner C, Gumbrell L, Dickens D, Ranson M
Primary Institution: CRC Department of Medical Oncology, Christie Hospital NHS Trust, Manchester
Hypothesis
The study aims to determine the maximum-tolerated dose and pharmacokinetic profile of CT-2584 HMS in adult patients with solid tumors.
Conclusion
CT-2584 HMS showed some antitumor effects, with one patient achieving a partial response, and a dose of 520 mg/m2 is recommended for further testing.
Supporting Evidence
- CT-2584 HMS was administered to 30 patients in a Phase I study.
- One patient with pleural mesothelioma achieved a partial response to treatment.
- The maximum-tolerated dose was determined to be 585 mg/m2.
Takeaway
Doctors tested a new drug called CT-2584 HMS on cancer patients to see how much they could safely take and if it helped them feel better.
Methodology
Patients received CT-2584 HMS as a continuous infusion for 6 hours for 5 consecutive days every 3 weeks, and pharmacokinetic studies were conducted.
Limitations
The study was limited by the small sample size and the occurrence of malaise and lethargy in patients.
Participant Demographics
Adult patients with solid tumors.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website